Abstract

The association between Organizing Pneumonia (OP) after lung transplantation with the development of acute rejection (AR) remains undefined. In addition, molecular allograft injury, as measured by donor-derived cell-free DNA (dd-cfDNA), during episodes of OP and its relationship to episodes of AR, chronic lung allograft dysfunction (CLAD) or death is unknown.This multicenter, prospective cohort study collected serial plasma samples from 188 lung transplant recipients for dd-cfDNA at the time of bronchoscopy with biopsy. Multivariable Cox regression was used to analyze the association between OP with the development of AR (antibody mediated rejection (AMR) and acute cellular rejection), CLAD and death. Multivariable models were performed to test the association of dd-cfDNA at OP with the risk of AR, CLAD or death.In multivariable analysis, OP was associated with increased risk of AMR (HR= 2.26, 95% CI 1.04-4.92, P =0.040) but not ACR (HR=1.29, 95% CI: 0.66 - 2.5, P = 0.45) or the composite outcome of CLAD or death (HR= 0.88, 95% CI, 0.47-1.65, P=0.69). Median levels of dd-cfDNA were higher in OP compared to stable controls (1.33% vs 0.43%, P = 0.0006). Multivariable analysis demonstrated that levels of dd-cfDNA at diagnosis of OP were associated with increased risk of both AMR (HR=1.29, 95% CI 1.03-1.62, P= 0.030) and death (HR=1.16, 95% CI, 1.02-1.31, P =0.026).OP is independently associated with an increased risk of AMR but not CLAD or death. The degree of molecular allograft injury at the diagnosis of OP may further predict the risk of AMR and death.

View details for DOI 10.1016/j.healun.2023.11.008

View details for PubMedID 37972825